Cure My Disease

Don't miss your cure!

 Log in / Sign up

French study maps the genetic and inflammatory roots of nerve damage

NCT ID NCT07851844

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 01, 2026 · Last updated Oct 02, 2026 · Updated 1 time

Summary

Researchers in France are studying adults diagnosed with genetic or inflammatory polyneuropathies, conditions that damage peripheral nerves. The study aims to describe the clinical, electrical, and genetic features of these patients by reviewing their routine medical records and test results. About 1,000 participants will be grouped by type and subtype of polyneuropathy to build a detailed picture of how these disorders appear and vary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
A detailed map of these nerve disorders could help doctors classify patients more accurately and point future research toward better treatments.
What could go wrong
This study only observes and records existing medical data, so it will not test any treatment or directly improve symptoms. Its value depends on how complete and consistent the records are.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults diagnosed with genetic or inflammatory polyneuropathy and followed in participating neurology centers in France.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years or older. * Patients with a diagnosis of genetic or inflammatory polyneuropathy, confirmed by complementary examinations performed as part of routine care, including genetic, biological and/or electrophysiological tests. Exclusion Criteria: \- Patient opposition to the use of their routine care data for research purposes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genetic and inflammatory polyneuropathies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Charcot-Marie-Tooth disease chronic inflammatory demyelinating polyradiculoneuropathy hereditary peripheral neuropathy neuritis polyneuritis polyneuropathy Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Genetic and inflammatory polyneuropathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Amiens-Picardie - Site Sud

    Amiens, France

  • CHU Angers

    Angers, France

  • CHU Grenoble - Site Sud

    Grenoble, France

  • CHU Nantes - Hôtel-Dieu - Hôpital Mère-Enfant

    Nantes, France

  • CHU de la Réunion - GH Sud Réunion - Saint-Pierre

    La Réunion, France

  • Centre Hospitalier Annecy Genevois

    Épagny, France

  • [email protected]

    Montpellier, France

  • Hôpital Ambroise Paré

    Paris, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Hôpital Bretonneau CHRU de Tours

    Tours, France

  • Hôpital Charles-Nicolle, CHU Rouen

    Rouen, France

  • Hôpital Dupuytren, CHU Limoges

    Limoges, France

  • Hôpital François Mitterrand, CHU Dijon

    Dijon, France

  • Hôpital Gabriel-Montpied, CHU Clermont-Ferrand

    Clermont-Ferrand, France

  • Hôpital La Pitié-Salpetrière

    Paris, France

  • Hôpital Maison Blanche, CHU Reims

    Reims, France

  • Hôpital Morvan, CHU Brest

    Brest, France

  • Hôpital Pasteur, CHU Nice

    Nice, France

  • Hôpital Pellegrin, CHU Bordeaux

    Bordeaux, France

  • Hôpital Pierre Wertheimer, HCL

    Bron, France

  • Hôpital Rangueil, CHU Toulouse

    Toulouse, France

  • Hôpital Raymond-Poincaré

    Garches, France

  • Hôpital Salengro, CHU de Lille

    Lille, France

  • Hôpital Universitaire Carémeau, CHU Nîmes

    Nîmes, France

  • Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg

    Strasbourg, France

  • Hôpital de la Timone, AP-HM

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.